Teva Pharmaceutical Industries TEVA stocks are buying and selling decrease Wednesday at the heels of the corporate’s fourth-quarter monetary effects. Right here’s what you want to grasp.
What To Know: Teva reported fourth-quarter income of $4.2 billion, beating analyst estimates of $4.13 billion, consistent with Benzinga Professional. The corporate reported fourth-quarter adjusted income of 71 cents in step with percentage, beating estimates of 70 cents in step with percentage.
“That specialize in rigorous execution of our Pivot to Enlargement technique all through the 12 months, we persevered to reach necessary milestones in each and every of its 4 pillars, together with surpassing the outlook for our key cutting edge merchandise, rising our generics industry throughout all segments, and accelerating our early-stage cutting edge pipeline, together with the sure Segment 2b effects for our duvakitug (anti-Tl1A) asset,” stated Richard Francis, president and CEO of Teva Pharmaceutical.
“Those effects pave the way in which for pivotal trials in Crohn’s illness and ulcerative colitis, in addition to, doubtlessly, different Immunological and fibrotic indications past, in collaboration with our spouse, Sanofi.”
Test This Out: Danaher This fall: EPS Pass over Expectancies Amid Diagnostics Phase Lag
Outlook: Teva Pharmaceutical expects full-year 2025 income to be within the vary of $16.8 billion to $17.4 billion as opposed to estimates of $17.05 billion. The corporate expects full-year adjusted income to be between $2.35 and $2.65 in step with percentage as opposed to estimates of $2.79 in step with percentage.
“In 2025, we look forward to additional growth in our key cutting edge expansion drivers, whilst additionally executing on our complicated generics and biosimilars industry, supported by way of new product launches. We also are excited to advance to Segment 3 trials for our duvakitug (anti-TL1A) asset,” Francis stated.
The corporate’s income steering seems to be weighing on stocks. Control is recently discussing the quarter on a convention name that kicked off at 8 a.m. ET.
TEVA Worth Motion: Teva Pharmaceutical stocks have been down 8.78% at $19.64 on the time of e-newsletter, consistent with Benzinga Professional.
Picture: courtesy of Teva Pharmaceutical.
Marketplace Information and Knowledge dropped at you by way of Benzinga APIs
© 2025 Benzinga.com. Benzinga does no longer supply funding recommendation. All rights reserved.
GIPHY App Key not set. Please check settings